Use of the tumor necrosis factor-blockers for Crohn's disease

doi:10.3748/wjg.v18.i35.4823

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7183)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-38) series.

Item

Count

PDF

639

HTML

6021

Figures (1-2)

265

Tables (1-38)

258

Sum=7183

Sep 21, 2012 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823

Table 23 Adalimumab for fistulizing Crohn's disease maintenance (%)

Study	Assessment week	Combined ADA group¹	PL	TG
CHARM	Closure
	26	30	13	17
	56	33	13	20

¹Statistically significant. Note that the two higher dose regimes of ADA do poorly for induction of fistulizing CD. The TG for IFX and ADA for fistula closure at 54-56 wk is a similar low value of 17%. PL: Placebo; TG: Therapeutic gain; ADA: Adalimumab; CHARM: Crohn's trial of the fully human antibody adalimumab for remission maintenance; IFX: Infliximab; CD: Crohn's disease. 140 mg q0w and 40 mg qw.

Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823